CACLP - The largest IVD Expo & Conference

Illumina, OrigiMed Collaborate to Develop Cancer Assays

Industry news | 28 August, 2018 | CACLP
NEW YORK (GenomeWeb) – Shanghai, China-based cancer precision medicine company OrigiMed said today it will collaborate with Illumina to develop oncology assays.
 
The firms will develop the new assays on Illumina's next-generation sequencing instruments for cancer molecular diagnostics. OrigiMed will also develop a bioinformatics solution for medical institutions.
 
OrigiMed is currently equipped with one of Illumina's NovaSeq 6000, four NextSeq 500s and one MiniSeq.
Filed under:
Press contact CACLP - The largest IVD Expo & Conference

Stay in touch with CACLP News

We deliver the latest IVD news straight to your inbox. Stay in touch with CACLP News, sign-up for our newsletter today.

  • Name *
  • Email *
  • Company name *
  • Country *
    CACLP - The largest IVD Expo & Conference

By subscribing our newsletter, you agree to our Privacy Policy. You can unsubscribe at anytime.

Share
Opening Countdown
0 0 0

Day(s)

0 0

Hour(s)

0 0

Min(s)

Room 2201-2203 & 2205, Cloud Nine Plaza
1118 West Yan’an Road
Shanghai, China
200052

Copyright © 2024 GL events Ruihe (Shanghai) Exhibition Co., Ltd. All Rights Reserved. ( 沪ICP备12004745号-1 )

We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy & Cookies for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

CACLP - The largest IVD Expo & Conference